Virological outcomes with <scp>Bictegravir/Emtricitabine/Tenofovir</scp> alafenamide ( <scp>B/F/TAF</scp> ) in people previously treated with darunavir‐based antiretroviral therapy

Substituting of Darunavir-based ART with B/F/TAF in this challenging population was associated with treatment-emergent INSTI and NRTI resistance. Historical resistance did not predict virological outcomes and treatment-emergent resistance did not preclude re-suppression on B/F/TAF, suggesting that adherence remains a major barrier to achieving long-term virological success.

Authors

Institutions

Publication Details

Journal
HIV Medicine
Published
2026-02-01
DOI
https://doi.org/10.1111/hiv.70204
Primary Topic
HIV/AIDS drug development and treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Virological outcomes with Bictegravir/Emtricitabine/Tenofovir alafenamide ( B/F/TAF ) in people previously treated with darunavir‐based antiretroviral therapy

Sally Hawkins, Rhianna Sheridan, Frank A. Post, Yasmin Osei‐Kuffour Ekert et al.
HIV Medicine
HIV/AIDS drug development and treatment
article

Virological outcomes with Bictegravir/Emtricitabine/Tenofovir alafenamide ( B/F/TAF ) in people previously treated with darunavir‐based antiretroviral therapy

Sally Hawkins, Rhianna Sheridan, Frank A. Post, Yasmin Osei‐Kuffour Ekert, Lucy Campbell, Kate Childs, Mark Zuckerman
article en

Abstract

Substituting of Darunavir-based ART with B/F/TAF in this challenging population was associated with treatment-emergent INSTI and NRTI resistance. Historical resistance did not predict virological outcomes and treatment-emergent resistance did not preclude re-suppression on B/F/TAF, suggesting that adherence remains a major barrier to achieving long-term virological success.

HIV Medicine
King's College London (GB), King's College Hospital NHS Foundation Trust (GB)
Openalex Percentile: Top 68%
HIV/AIDS drug development and treatment
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Virological outcomes with <scp>Bictegravir/Emtricitabine/Tenofovir</scp> alafenamide ( <scp>B/F/TAF</scp> ) in people previously treated with darunavir‐based antiretroviral therapy — Sally Hawkins, Rhianna Sheridan, et al. · HIV Medicine (2026) | TGRS Research Map | TGRS